VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AORTArtivion, Inc.
$21.19$1.0B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAORTP/E History

AORT logoArtivion, Inc. (AORT) P/E Ratio History

Undervalued

Trading at 100.9x vs 5Y avg 287.7x · 65th percentile · Below historical baseline · Data 1994–2026

Current P/E (TTM)
100.9x
-65% vs 5Y avg
5Y Avg P/E
287.7x
Median 81.7x
5Y Percentile
65th
Mid-range
PEG Ratio
N/A
5-Year P/E Range
100.9x
Min19.4xMedian81.7xMax2513.9x
TTM EPS$0.24
Price$21.19
Earnings Yield0.99%
EPS Growth (1Y)165.6%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Artivion, Inc. (AORT) trades at a price-to-earnings ratio of 100.9x, with a stock price of $21.19 and trailing twelve-month earnings per share of $0.24.

The current P/E is 65% below its 5-year average of 287.7x. Over the past five years, AORT's P/E has ranged from a low of 19.4x to a high of 2513.9x, placing the current valuation at the 65th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, AORT trades at a 356% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, AORT commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AORT DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

AORT Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
100.9vs22.1
+356%
Above Sector
vs. S&P 500
100.9vs24.4
+313%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 166% EPS growth (1Y)

AORT P/E vs Peers

Cardiovascular and heart rhythm devices peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
TMDX logoTMDXTransMedics Group, Inc.
$3B16.2Lowest-+382%
GMED logoGMEDGlobus Medical, Inc.
$11B20.20.65Best+423%Best
LMAT logoLMATLeMaitre Vascular, Inc.
$2B37.31.93+31%
MDT logoMDTMedtronic plc
$102B22.0-+31%
EW logoEWEdwards Lifesciences Corporation
$50B47.76.74-74%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

AORT Historical P/E Data (1994–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$36.62$0.24154.5x+17%
FY2025 Q4Dec 31 2025$45.61$0.20232.0x+76%
FY2021 Q3-$22.29$0.03665.4x+403%
FY2019 Q4-$27.09$0.04677.3x+412%
FY2019 Q3Sep 30 2019$27.15$0.012513.9x+1802%
FY2019 Q2Jun 30 2019$29.93$0.05550.2x+316%
FY2017 Q4Dec 31 2017$19.15$0.10188.5x+43%
FY2017 Q3Sep 30 2017$22.70$0.2881.1x-39%
FY2017 Q2Jun 30 2017$19.95$0.3360.5x-54%
FY2017 Q1Mar 31 2017$16.65$0.3153.7x-59%
FY2016 Q4Dec 31 2016$19.15$0.3358.0x-56%
FY2016 Q3Sep 30 2016$17.57$0.3353.2x-60%
FY2016 Q2-$11.81$0.3138.1x-71%
FY2016 Q1-$10.75$0.2248.4x-63%
FY2015 Q4-$10.78$0.1381.7x-38%
FY2015 Q3Sep 30 2015$9.73$0.1191.0x-31%
FY2015 Q2-$11.28$0.1296.5x-27%
FY2015 Q1-$10.37$0.2148.2x-64%
FY2014 Q4Dec 31 2014$11.33$0.2742.8x-68%
FY2014 Q3-$9.87$0.5119.4x-85%
FY2014 Q2Jun 30 2014$8.95$0.5416.6x-87%
FY2014 Q1Mar 31 2014$9.96$0.5219.2x-86%
FY2013 Q4-$11.09$0.5619.8x-85%
FY2013 Q3Sep 30 2013$7.00$0.3221.9x-83%
FY2013 Q2Jun 30 2013$6.26$0.2723.2x-82%
FY2013 Q1Mar 31 2013$6.01$0.3318.2x-86%
FY2012 Q4Dec 31 2012$6.23$0.2921.5x-84%
FY2012 Q3Sep 30 2012$6.72$0.2923.3x-82%
FY2012 Q2Jun 30 2012$5.23$0.3017.6x-87%
FY2012 Q1Mar 31 2012$5.27$0.2521.3x-84%
FY2011 Q4Dec 31 2011$4.80$0.2717.9x-86%
FY2011 Q3Sep 30 2011$4.49$0.2816.3x-88%
FY2011 Q2-$5.60$0.1058.3x-56%
FY2011 Q1-$6.10$0.1348.4x-63%
FY2010 Q4Dec 31 2010$5.42$0.1439.9x-70%
FY2010 Q3-$6.07$0.1442.4x-68%
FY2010 Q2Jun 30 2010$5.39$0.3216.7x-87%
FY2010 Q1Mar 31 2010$6.47$0.3120.7x-84%
FY2009 Q4-$6.42$0.3120.5x-84%
FY2009 Q3Sep 30 2009$7.97$1.037.7x-94%
FY2009 Q2-$5.54$1.085.1x-96%
FY2009 Q1-$5.18$1.134.6x-97%
FY2008 Q4Dec 31 2008$9.71$1.168.4x-94%
FY2008 Q3-$13.12$0.4628.8x-78%
FY2008 Q2Jun 30 2008$11.44$0.4128.2x-79%
FY2008 Q1Mar 31 2008$9.40$0.3229.8x-77%
FY2007 Q4Dec 31 2007$7.95$0.2631.2x-76%
FY2007 Q3Sep 30 2007$9.45$0.1659.8x-55%
FY2007 Q2Jun 30 2007$13.01$0.1682.3x-38%
FY2007 Q1Mar 31 2007$8.41$0.1272.1x-45%
FY2006 Q4Dec 31 2006$7.65$0.001593.8x+1106%
FY2002 Q2Jun 30 2002$32.12$0.09341.7x+159%
FY2002 Q1Mar 31 2002$41.80$0.5082.9x-37%
FY2001 Q4Dec 31 2001$60.00$0.47126.6x-4%
FY2001 Q3Sep 30 2001$75.22$0.50150.4x+14%
FY2001 Q2Jun 30 2001$81.82$0.48170.5x+29%
FY2001 Q1Mar 31 2001$51.86$0.46112.7x-15%
FY2000 Q4Dec 31 2000$60.50$0.42144.0x+9%
FY2000 Q3Sep 30 2000$46.25$0.30153.5x+16%
FY2000 Q2Jun 30 2000$30.67$0.27113.0x-14%
FY2000 Q1Mar 31 2000$24.00$0.2594.2x-29%
FY1999 Q4Dec 31 1999$15.67$0.2366.8x-49%
FY1999 Q3-$16.67$0.3350.8x-62%
FY1999 Q2Jun 30 1999$16.33$0.3448.3x-63%
FY1999 Q1Mar 31 1999$14.67$0.3541.3x-69%
FY1998 Q4-$15.83$0.3643.4x-67%
FY1998 Q3Sep 30 1998$21.00$0.3363.4x-52%
FY1998 Q2-$21.00$0.3363.4x-52%
FY1998 Q1-$22.67$0.3075.3x-43%
FY1997 Q4Dec 31 1997$18.17$0.2963.1x-52%
FY1997 Q3-$19.92$0.3164.8x-51%
FY1997 Q2Jun 30 1997$15.92$0.3053.5x-59%
FY1997 Q1Mar 31 1997$11.17$0.2938.9x-71%
FY1996 Q4-$16.67$0.2761.7x-53%
FY1996 Q3Sep 30 1996$17.00$0.2568.8x-48%
FY1996 Q2Jun 30 1996$24.67$0.21119.2x-10%
FY1996 Q1Mar 31 1996$14.33$0.1881.0x-39%
FY1995 Q4Dec 31 1995$10.33$0.1665.8x-50%
FY1995 Q3Sep 30 1995$12.00$0.1675.9x-43%
FY1995 Q2Jun 30 1995$7.50$0.1454.3x-59%
FY1995 Q1Mar 31 1995$5.00$0.1242.4x-68%
FY1994 Q4Dec 31 1994$4.33$0.1044.2x-67%
FY1994 Q3Sep 30 1994$5.42$0.0773.2x-45%
FY1994 Q2-$3.33$0.0561.7x-53%

Average P/E for displayed period: 132.2x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

32+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AORT — Frequently Asked Questions

Quick answers to the most common questions about buying AORT stock.

What is AORT's P/E ratio?

Artivion, Inc. (AORT) trailing twelve-month P/E ratio is 100.9x, based on TTM diluted EPS of $0.24. The 5-year average P/E is 287.7x and the historical range spans 19.4x to 2513.9x.

Is AORT stock overvalued or undervalued?

AORT trades at 100.9x P/E, below its 5-year average of 287.7x. At the 65th percentile of its historical range (19.4x–2513.9x), the stock is priced at a discount to its own history.

Is AORT stock expensive?

No, AORT is not expensive on a historical basis. The current P/E of 100.9x is below the 5-year average of 287.7x and sits at the 65th percentile of its valuation range.

What is AORT's historical P/E range?

Over the past 5 years, AORT's P/E ratio has ranged from 19.4x to 2513.9x, with a median of 81.7x and an average of 287.7x. The current P/E of 100.9x places the stock at the 65th percentile of this range. Full historical data spans 1994–2026.

How does AORT's P/E compare to the S&P 500?

AORT trades at 100.9x P/E versus the S&P 500 median of 24.4x. The 314% premium to the market typically reflects higher expected earnings growth or quality.

How does AORT's valuation compare to Healthcare peers?

Artivion, Inc. P/E of 100.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is AORT's PEG ratio?

AORT PEG ratio is N/A, based on a P/E of 100.9x and EPS growth of 165.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is AORT's earnings yield?

AORT earnings yield is 0.99%, the inverse of its 100.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

AORT P/E Ratio History (1994–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current154.5x
Period Avg287.7x
Range19.4x - 2513.9x
Change+698%
20 quartersSep 30, 2014 - Mar 31, 2026